Immune checkpoint inhibitors (ICI) could be offered to stage IV lung adenocarcinoma patients according to the tumor genotype, PD-L1 expression, patient’s performance status and comorbidities, with a substantial improvement. This evidence concerns the gene CD274 and neoplasm.